SKLB-0322
/ State Key Laboratory of Biotherapy and Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 06, 2021
SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer
(ESMO-TAT 2022)
- "Our data clarified that SKLB-0322 is an EZH2 covalent inhibitor for ovarian cancer therapy which is worthy of further evaluation."
Oncology • Ovarian Cancer • Solid Tumor • EZH2
1 to 1
Of
1
Go to page
1